title: Autoimmune uveitis: a retrospective analysis of 104 patients from a tertiary reference center.
abstract: BACKGROUND
  The aim of this study was to identify the main features of a cohort of Caucasian patients with idiopathic (I) and systemic disease-associated (SDA) autoimmune uveitis (AU) who were followed up at a single tertiary reference center. The study consisted of a retrospective analysis of the demographic, clinical, and laboratory features and the response to treatment of 104 patients with AU evaluated between 2004 and 2013, with a median follow-up of 4.8 years. The primary outcome measure was the response to systemic treatment after 24 months of therapy. The data are expressed as the range, percentage, or mean ± standard error. Categorical variables were assessed by Fisher's exact test.
  
  
  RESULTS
  The mean age at diagnosis was 40.1 ± 17.8 years for men and 44.1 ± 15.3 years for women. There was a slight female predominance. Of the 104 patients, 72.1% had I-AU and 27.9% SDA-AU. The most frequent associations were with ankylosing spondyloarthritis, autoimmune thyroiditis, inflammatory bowel diseases, and Behcet's disease. Symptoms at presentation consisted of eye redness and pain (28.8%), decreased visual acuity (25.9%), and floaters (18.3%). Complications included cataracts (24%), retinal neovascularization (16.3%), chorio-retinal scars (10.6%), cystoid macular edema (8.6%), glaucoma/ocular hypertension (7.7%), epiretinal membranes (4.8%), and retinal detachment (3.8%). The prevalence of autoantibodies, mostly antinuclear antibodies, was comparable between the I-AU and SDA-AU groups. Fisher's exact test showed a direct correlation between patients with class I HLA B27, Cw8, B5 (51, 52), B51, or Cw2 and the presence of AU, whereas among patients with class II HLA, only DQ1 was a predisposing factor for AU. The therapeutic spectrum included corticosteroids and immunosuppressive agents, given either alone or in various combinations according to the severity of AU and the extent of the clinical response. Among the immunosuppressive drugs, azathioprine was preferentially used for anterior uveitis, and cyclosporine-A for intermediate and posterior uveitis. An assessment of the patients after 24 months of therapy showed a complete remission in 43.3% and a significant clinical improvement in 26.9%.
  
  
  CONCLUSIONS
  At our tertiary reference center, the prevalence in Caucasian patients of I-AU was approximately 2.5-fold higher than that of SDA-AU. Our findings point to the need for a patient-tailored therapeutic approach according to the anatomic site and the severity of AU. Therapy should be prolonged, over a period of months and even up to 1-2 years, in order to achieve stable control of the disease and to prevent severe complications. The outcome of SDA-AU is also influenced by treatment of the underlying systemic disease. Additional controlled trials are needed to assess the efficacy and the long-term safety of both the prescribed therapeutic agents and their combinations.
authors.affiliation: Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Piazza G. Cesare 11, Bari 70124, Italy.
authors.forename: Marcella
authors.initials: M
authors.lastname: Prete
authors.affiliation: Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Medical School, Piazza G. Cesare 11, Bari 70124, Italy.
authors.forename: Silvana
authors.initials: S
authors.lastname: Guerriero
authors.affiliation: Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Medical School, Piazza G. Cesare 11, Bari 70124, Italy.
authors.forename: Rosanna
authors.initials: R
authors.lastname: Dammacco
authors.affiliation: Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Piazza G. Cesare 11, Bari 70124, Italy.
authors.forename: Maria Celeste
authors.initials: MC
authors.lastname: Fatone
authors.affiliation: Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Piazza G. Cesare 11, Bari 70124, Italy.
authors.forename: Angelo
authors.initials: A
authors.lastname: Vacca
authors.affiliation: Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Piazza G. Cesare 11, Bari 70124, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Dammacco
authors.affiliation: Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Piazza G. Cesare 11, Bari 70124, Italy.
authors.forename: Vito
authors.initials: V
authors.lastname: Racanelli
keywords: Ankylosing spondyloarthritis; Autoimmune uveitis; Behcet's disease; Class I and II HLA; Corticosteroids; Immunosuppressive drugs
references.citation: Am J Ophthalmol. 2005 Sep;140(3):509-16
references.pmid: 16196117
references.citation: Br J Ophthalmol. 2006 Jan;90(1):103-8
references.pmid: 16361678
references.citation: Eye (Lond). 2012 Jan;26(1):17-28
references.pmid: 21960067
references.citation: Mol Vis. 2013;19:184-95
references.pmid: 23378732
references.citation: Ocul Immunol Inflamm. 2015 Apr;23(2):118-26
references.pmid: 24295124
references.citation: Clin Exp Ophthalmol. 2009 Aug;37(6):595-601
references.pmid: 19702710
references.citation: Am J Ophthalmol. 2001 May;131(5):657-9
references.pmid: 11336946
references.citation: Acta Ophthalmol. 2009 Jun;87(4):424-8
references.pmid: 18652578
references.citation: Indian J Ophthalmol. 2007 May-Jun;55(3):173-83
references.pmid: 17456933
references.citation: Mod Rheumatol. 2008;18(4):354-8
references.pmid: 18427720
references.citation: Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2547-54
references.pmid: 16723469
references.citation: Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2465-71
references.pmid: 15980237
references.citation: Mol Vis. 2011;17:2970-7
references.pmid: 22128242
references.citation: Am J Ophthalmol. 2008 Mar;145(3):463-471
references.pmid: 18061135
references.citation: Ocul Immunol Inflamm. 2012 Aug;20(4):255-61
references.pmid: 22564107
references.citation: J Clin Invest. 2010 Sep;120(9):3073-83
references.pmid: 20811163
references.citation: Arthritis Rheum. 1997 Feb;40(2):358-70
references.pmid: 9041948
references.citation: Ophthalmology. 2004 Mar;111(3):491-500; discussion 500
references.pmid: 15019324
references.citation: Ocul Immunol Inflamm. 2010 Jan;18(1):2-4
references.pmid: 20128640
references.citation: Semin Arthritis Rheum. 2011 Feb;40(4):314-23
references.pmid: 20656330
references.citation: Ocul Immunol Inflamm. 2011 Apr;19(2):108-14
references.pmid: 21428748
references.citation: PLoS One. 2012;7(1):e29742
references.pmid: 22238646
references.citation: Clin Rev Allergy Immunol. 2011 Oct;41(2):214-23
references.pmid: 21913066
references.citation: Acta Ophthalmol Scand. 2001 Feb;79(1):64-8
references.pmid: 11167291
references.citation: Expert Opin Emerg Drugs. 2011 Jun;16(2):309-22
references.pmid: 21210752
references.citation: Curr Allergy Asthma Rep. 2014 Jan;14(1):409
references.pmid: 24338488
references.citation: Orphanet J Rare Dis. 2012 Aug 29;7:57
references.pmid: 22932001
references.citation: Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3475-82
references.pmid: 18421089
references.citation: J Interferon Cytokine Res. 2011 Oct;31(10):733-44
references.pmid: 21787221